Ankyra Therapeutics Announces First Visceral Tumor Patient Dosed in Phase 1 ANCHOR Clinical Trial of ANK-101, an Anchored Interleukin-12 (IL-12)

by Anand Patadiya | Nov 5, 2024

Safety and tolerability to be determined at up to 5 study sites in the United States and Canada November 5, 2024 (Cambridge, MA) – Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored therapy to treat cancer, today announced the first...

Immunotherapy Trials Show Promise for Treating Canine Melanoma

by Anand Patadiya | Oct 2, 2024

Ankyra Therapeutics announces $45 Million Series B Financing and Appoints Howard L. Kaufman M.D. as Chief Medical Officer

by Anand Patadiya | Oct 2, 2024

BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents that boost anti-tumor immune responses, today announced the closing of a $45 million Series B financing. Proceeds from the...

Ankyra Therapeutics Appoints Howard L. Kaufman, M.D. as President and Chief Executive Officer

by Anand Patadiya | Oct 2, 2024

Highly Accomplished Thought Leader with Proven Track Record of Immunotherapy Drug Development BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents, announced today that the Board...

Ankyra Therapeutics Announces Cooperative Research and Development Agreement with the National Cancer Institute

by Anand Patadiya | Oct 2, 2024

BOSTON, Mass.–(BUSINESS WIRE)— Ankyra Therapeutics is pleased to announce that it has established a formal Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to pursue basic, translational and clinical research using Ankyra...